Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by Capitalistaon Oct 04, 2022 5:11am

173 Views

Post# 35003289

RE:RE:RE:RE:RE:RE:RE:Adlai Nortye

Noteable wrote: Have I answered your question Capitalista?

Sorry for the slow reply on this, Noteable - I've been out of internet access for the past few days.

You've partially answered my question. I'm wondering why AN would willingly embargo study results when they don't receive any particular benefit from doing so. In fact, AN would incur some time risk from delaying results, assuming the results are positive.

However, this scenario you have presented is speculation so other factors may be responsible for the disappearance of the study details from AN's site (I can't find any mention of AN1004 for some reason).

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects